查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1572042

抗血栓药物市场：按药物类别、给药途径、应用、最终用户、年龄组划分 - 全球预测 2025-2030

Antithrombotic Drugs Market by Drug Class (Antiplatelet Agents, Direct Thrombin Inhibitors, Factor Xa Inhibitors), Route of Administration (Injectable, Oral), Application, End User, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗血栓药物市值为400.8亿美元，预计2024年将达到424.7亿美元，复合年增长率为6.04%，到2030年将达到604.5亿美元。

抗血栓药物市场包括多种旨在预防血栓症的产品，包括抗凝血剂、抗血小板剂和血栓溶解剂。这些药物对于深层静脉栓塞症、肺动脉栓塞、心肌梗塞和中风等疾病的管理和预防至关重要，是心血管疾病管理的基石。全球心血管疾病、肥胖和久坐生活方式的发病率不断增加，推动了对此类药物的需求。应用范围涵盖医院、门诊手术中心和居家医疗，最终用户包括医疗保健提供者和患者。关键的成长要素包括更容易患血栓性疾病的人口老化以及导致更有效药物配方开发的技术进步。此外，越来越多的人患有与文明病，这产生了对预防性医疗措施的需求，这为正在开发医疗基础设施的新兴市场创造了潜在的成长机会。然而，市场面临药物开发高成本、监管挑战以及长期抗凝血治疗副作用导致的依从性问题等限制。复杂的监管环境和严重药物交互作用的风险进一步阻碍了成长。创新技术和研究领域正在开拓，包括开发新型口服抗凝血剂（NOAC），以提供更好的安全性并减少监测需求。此外，个人化医疗利用基因检测为个别患者量身定制治疗方案，是实现差异化和市场渗透的一条有前途的途径。由于激烈的市场竞争和快速的技术创新，主要企业正专注于策略联盟、合併和研究合作，以加强其产品组合和地理覆盖范围。为了利用这些机会，公司正在投资研发以克服已发现的局限性，同时创造开拓的市场，特别开拓不断增长的老年人口和不断上升的血栓性疾病患病率。

主要市场统计
基准年[2023] 400.8亿美元
预测年份 [2024] 424.7亿美元
预测年份 [2030] 604.5亿美元
复合年增长率（%） 6.04%

市场动态：揭示快速发展的抗血栓药物市场的关键市场洞察

供需的动态交互作用正在改变抗血栓药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 越来越多的老年人口容易发生血栓事件，需要持续的药物治疗
    • 透过扩大新兴国家的医疗基础设施改善医疗服务
    • 由于医疗成本增加和医学研究投资促进药物开发
    • 製药公司之间的联盟和伙伴关係推动抗血栓治疗的创新
  • 市场限制因素
    • 与抗血栓药物相关的副作用和安全问题限制了临床接受度
    • 专利到期和学名药竞争降低了抗血栓药物的盈利和市场机会
  • 市场机会
    • 扩大医疗基础设施以推动抗血栓药物在新兴市场的采用
    • 药物传递系统的技术进步提高了抗血栓药物的有效性
    • 药厂与研究机构合作加速抗血栓药物研发
  • 市场挑战
    • 解决抗血栓药物开发和行销中病患的安全性和有效性问题
    • 应对抗血栓药物市场中生物技术和个人化医疗的快速发展

波特五力：驾驭抗血栓药物市场的策略工具

波特的五力框架是了解抗血栓药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗血栓药物市场的外部影响

外部宏观环境因素在塑造抗血栓药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗血栓药物市场竞争状况

抗血栓药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗血栓药物市场供应商绩效评估

FPNV定位矩阵是评估抗血栓药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗血栓药物市场的成功之路

抗血栓药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 越来越多的老年人口容易发生血栓症，需要持续用药
      • 扩大新兴国家的医疗基础设施改善医疗服务的可近性
      • 医疗保健成本上升和医学研究投资推动药物开发
      • 製药公司之间的合作与伙伴关係，促进抗血栓治疗的创新
    • 抑制因素
      • 与抗血栓药物相关的副作用和安全问题限制了临床接受度
      • 专利到期和学名药竞争，降低了抗血栓药物的盈利和市场机会。
    • 机会
      • 扩大医疗基础设施推动新兴市场采用抗血栓药物
      • 药物传递系统的技术进步提高了抗血栓药物的有效性
      • 製药公司与研究机构合作加速抗血栓药物开发
    • 任务
      • 抗血栓药物在开发和行销过程中解决了患者的安全性和有效性问题
      • 抗血栓药物市场与生物技术和个人化医疗的快速发展保持同步
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的抗血栓药物市场

  • 抗血小板药
    • 阿斯匹灵
    • Clopidogrel
    • 普拉格雷
  • 直接凝血酶抑制剂
    • Dabigatran
  • Xa因子抑制剂
    • Apixaban
    • 艾多沙班
    • Rivaroxaban
  • 维生素K拮抗剂
    • Warfarin

第七章抗血栓药物市场：依给药途径

  • 可注射的
  • 口服

第八章抗血栓药物市场：依应用分类

  • 急性冠状动脉症候群
  • 心房颤动
  • 深部静脉血栓和肺栓塞

第九章抗血栓药物市场：依最终用户分类

  • 门诊手术中心
  • 诊所
  • 医院

第10章抗血栓药物市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第十一章美洲抗血栓药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太抗血栓药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲抗血栓药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C01CD

The Antithrombotic Drugs Market was valued at USD 40.08 billion in 2023, expected to reach USD 42.47 billion in 2024, and is projected to grow at a CAGR of 6.04%, to USD 60.45 billion by 2030.

The antithrombotic drugs market encapsulates a wide range of products aimed at preventing thrombosis, including anticoagulants, antiplatelet drugs, and thrombolytic drugs. These medications are crucial in managing and preventing conditions such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke, making them a cornerstone of cardiovascular disease management. The necessity for these drugs is driven by the increasing incidence of cardiovascular disorders, obesity, and sedentary lifestyles globally. Applications span across hospital settings, ambulatory surgical centers, and home care, with end-users including healthcare providers and patients. Key growth influencers include the aging population, which is more susceptible to thrombotic diseases, and ongoing technological advancements leading to the development of more effective drug formulations. Furthermore, an increasing number of individuals with lifestyle diseases calls for preventive healthcare measures, creating potential growth opportunities in emerging markets with rising healthcare infrastructure. However, the market faces limitations such as high costs associated with drug development, regulatory challenges, and adherence issues due to the side effects of long-term anticoagulation therapy. The complex regulatory landscape and risk of significant drug interactions pose additional barriers to growth. Innovations and research areas ripe for exploration include the development of novel oral anticoagulants (NOACs), which offer better safety profiles and reduced monitoring requirements. Furthermore, personalized medicine, leveraging genetic testing to tailor treatments to individual patients, offers a promising avenue for differentiation and market penetration. The market is highly competitive with a nature of rapid innovation, leading pharmaceutical companies to focus on strategic partnerships, mergers, and collaborations to enhance their portfolios and geographic reach. To capitalize on these opportunities, companies should invest in R&D and focus on overcoming the identified limitations while exploring untapped markets, particularly in regions with growing geriatric populations and rising incidences of thrombotic diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 40.08 billion
Estimated Year [2024] USD 42.47 billion
Forecast Year [2030] USD 60.45 billion
CAGR (%) 6.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antithrombotic Drugs Market

The Antithrombotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population susceptible to thrombotic events requiring consistent medication
    • Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
    • Rising healthcare expenditure and investment in medical research boosting drug development
    • Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
  • Market Restraints
    • Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
    • Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
  • Market Opportunities
    • Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
    • Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
    • Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
  • Market Challenges
    • Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
    • Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market

Porter's Five Forces: A Strategic Tool for Navigating the Antithrombotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antithrombotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antithrombotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antithrombotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antithrombotic Drugs Market

A detailed market share analysis in the Antithrombotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antithrombotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antithrombotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antithrombotic Drugs Market

A strategic analysis of the Antithrombotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antithrombotic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alere Inc., Aralez Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Portola Pharmaceuticals, Roche Holding AG, Sanofi S.A., and The Medicines Company.

Market Segmentation & Coverage

This research report categorizes the Antithrombotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Antiplatelet Agents, Direct Thrombin Inhibitors, Factor Xa Inhibitors, and Vitamin K Antagonists. The Antiplatelet Agents is further studied across Aspirin, Clopidogrel, and Prasugrel. The Direct Thrombin Inhibitors is further studied across Dabigatran. The Factor Xa Inhibitors is further studied across Apixaban, Edoxaban, and Rivaroxaban. The Vitamin K Antagonists is further studied across Warfarin.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Application, market is studied across Acute Coronary Syndrome, Atrial Fibrillation, and DVT and PE.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population susceptible to thrombotic events requiring consistent medication
      • 5.1.1.2. Expansion of healthcare infrastructure in emerging economies improving accessibility to antithrombotic drugs
      • 5.1.1.3. Rising healthcare expenditure and investment in medical research boosting drug development
      • 5.1.1.4. Collaborations and partnerships among pharmaceutical companies fostering innovation in antithrombotic treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects and safety concerns associated with antithrombotic drugs limit their clinical acceptance
      • 5.1.2.2. Patent expirations and generic competition reduce the profitability and market opportunities for antithrombotic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of healthcare infrastructure driving adoption of antithrombotic drugs in emerging markets
      • 5.1.3.2. Technological advancements in drug delivery systems enhancing efficacy of antithrombotic drugs
      • 5.1.3.3. Collaborations between pharmaceutical companies and research institutes accelerating antithrombotic drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing patient safety and efficacy concerns while developing and marketing antithrombotic drugs
      • 5.1.4.2. Keeping pace with rapid advancements in biotechnology and personalized medicine in the antithrombotic drugs market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antithrombotic Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Antiplatelet Agents
    • 6.2.1. Aspirin
    • 6.2.2. Clopidogrel
    • 6.2.3. Prasugrel
  • 6.3. Direct Thrombin Inhibitors
    • 6.3.1. Dabigatran
  • 6.4. Factor Xa Inhibitors
    • 6.4.1. Apixaban
    • 6.4.2. Edoxaban
    • 6.4.3. Rivaroxaban
  • 6.5. Vitamin K Antagonists
    • 6.5.1. Warfarin

7. Antithrombotic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Antithrombotic Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Coronary Syndrome
  • 8.3. Atrial Fibrillation
  • 8.4. DVT and PE

9. Antithrombotic Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Clinics
  • 9.4. Hospitals

10. Antithrombotic Drugs Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Antithrombotic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antithrombotic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antithrombotic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. ANTITHROMBOTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTITHROMBOTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTITHROMBOTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PRASUGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DVT AND PE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES ANTITHROMBOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR ANTITHROMBOTIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTI